Vertex Pharmaceuticals (VRTX) Change in Cash (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Cash for 18 years, with the latest figure at $417.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 268.46% year-over-year to $417.1 million; the trailing twelve-month figure through Mar 2026 stood at $819.5 million (up 118.28% YoY), and the FY2025 full-year result was $515.6 million, up 108.89% from the prior year.
• Change in Cash for Q1 2026 stood at $417.1 million, up from $140.0 million in the prior quarter.
• The five-year high for Change in Cash was $1.3 billion in Q4 2022, with the low at -$4.6 billion in Q2 2024.
• Average Change in Cash over 5 years is -$76.2 million, with a median of $296.6 million recorded in 2025.
• Year-over-year, Change in Cash jumped 554.96% in 2022 and sank 633.74% in 2024.
• Tracing VRTX's Change in Cash over 5 years: stood at $1.3 billion in 2022, then sank by 155.75% to -$744.3 million in 2023, then climbed by 9.19% to -$675.9 million in 2024, then soared by 120.71% to $140.0 million in 2025, then jumped by 197.93% to $417.1 million in 2026.
• The last three Change in Cash figures came in at $417.1 million (Q1 2026), $140.0 million (Q4 2025), and -$34.2 million (Q3 2025), per Business Quant data.

Peer Comparison